Similar Perceptions on Continuous Glucose Monitor Use amongst Youth with Type 1 and Type 2 Diabetes

Background and Objective. Continuous glucose monitoring (CGM) is shown to improve quality of life (QoL) in youth with type 1 diabetes (T1D), yet there is limited data on CGM in youth with type 2 diabetes (T2D). The objective was to compare perceptions of CGM and QoL between patients with T1D and T2D. Methods. Youth with T1D and T2D (currently on insulin therapy) without current CGM participated in a prospective CGM study and were given a series of questionnaires when starting CGM intervention. BenCGM and BurCGM questionnaires assessed the participant's perspectives on continuous glucose monitor use, while DDS surveys assessed participants' QoL associated with diabetes. Survey results were compared between T1D and T2D groups, and multivariable analysis was used to assess differences in perceptions of continuous glucose monitor use in youth with diabetes. Results. Participants with T1D (n = 26, 65.4% male, 42.3% non-Hispanic black, median age 14.2 years, median HbA1c 10.3%) and T2D (n = 41, 39% male, 80.5% non-Hispanic black, median age 16.2 years, median HbA1c 10.3%) scored similarly on the BenCGM, BurCGM, and DDS surveys. In a pooled analysis of both T1D and T2D, there was no difference in survey results by race/ethnicity, but female youth had an increased odd of diabetes-related distress, specifically regimen-related distress. Conclusions. Youth with T1D and T2D on insulin therapy report similar perspectives on continuous glucose monitor use and QoL measures. Insulin use in both T1D and T2D may carry a similar burden of management, and CGM may help improve quality of life. Trial registration: This trial is registered with NCT04721145, NCT04721158.

Automated summary

The objective of this study was to compare perceptions of continuous glucose monitoring (CGM) and quality of life (QoL) between patients with type 1 diabetes (T1D) and type 2 diabetes (T2D). Questionnaires were given to youth with T1D and T2D currently on insulin therapy, and the results showed that both groups had similar perspectives on CGM and QoL measures. This suggests that insulin use in both T1D and T2D may carry a similar burden of management, and CGM may help improve quality of life.